OligoModify Date : 2018-11-17 23:41:25

▣ Oligo

With more than 30 years of experience and technology, ST Pharm's oligo CDMO business produces cGMP oligonucleotide-based products, such as antisense drugs, which are an area of gene therapy.

In line with the rapidly increasing importance of basic research, we have also begun RNAi synthesis services and are consigned from nmole to g scale. We also provide the highest level of research services such as analytical research and documentation such as AMD, AMQ and AMV. Furthermore, we are producing a large number of nucleosides and amidites, which are oligonucleotides. It is the world's No.1 company with the best expertise in oligonucleotides such as antisense drug, Immune stimulators, aptamer, decoy, siRNA, microRNA family of natural and modified oligonucleotides.

▣ Oligonucleotide Treatment

There are various attempts to develop synthetic genes as drugs around the world, such as RNAi (siRNA) and Antisense.

1. Antisense

Oligonucleotide treatment in the form of single stranded DNA of 19-25mer length. MRNA, combined with antisense oligonucleotide therapeutics with complementary sequences, is broken down by RNase H and not expressed as protein, which regulates gene expression.

2. siRNA (small interfering RNA)

Oligonucleotide treatment in the form of double stranded RNA of 19 ~ 27mer length. It uses RNA interference to treat diseases. When certain mRNAs with complementary sequences to siRNAs bind, mRNAs are degraded within the RNA-induced silencing complex (RISC), preventing them from being expressed as proteins. Unlike miRNAs, which are originally present in vivo, siRNAs are developed by modifying sequences to better bind to specific mRNAs in order to improve disease treatment.

3. miRNA (microRNA; Antagomir)

Oligonucleotide treatment in the form of single stranded RNA with a length of 19 ~ 25mer. It uses RNA interference1 to treat diseases. Unlike siRNAs with altered sequences, miRNAs are single stranded RNAs in non-coding regions that exist in vivo. It binds to multiple target mRNAs with similar sequences and regulates gene expression by preventing the protein from being expressed.

4. Aptamer

29-40mer long DNA or RNA oligonucleotide treatment. Unlike other oligonucleotide therapeutics that act by complementary binding between bases, they form a tertiary structure like antibodies and bind to targets, thus acting as a therapeutic agent for disease (hence, called chemical antibodies). Targets include proteins, nucleic acids, cells, tissues, organisms, etc., and are used in diagnostics and research fields in addition to therapeutics.

5.Others1) CpG: It is complemented with TLR9 (Toll-like Receptor 9) to enhance immune function and is being developed for the purpose of vaccine adjuvant, chemotherapy or immune disease. 2) Decoy: Combines with transcription factor to inhibit gene expression.